Equities
  • Price (USD)149.45
  • Today's Change-4.94 / -3.20%
  • Shares traded666.59k
  • 1 Year change-20.74%
  • Beta0.3840
Data delayed at least 15 minutes, as of Mar 28 2024 20:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.

  • Revenue in USD (TTM)1.83bn
  • Net income in USD-440.24m
  • Incorporated2003
  • Employees2.10k
  • Location
    Alnylam Pharmaceuticals Inc675 W Kendall StCAMBRIDGE 02142-1168United StatesUSA
  • Phone+1 (617) 551-8200
  • Fax+1 (617) 551-8101
  • Websitehttps://www.alnylam.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Sarepta Therapeutics Inc1.24bn-535.98m12.15bn1.31k--14.12--9.77-6.15-6.1513.469.170.3890.57084.04946,222.30-16.77-21.63-20.94-25.7587.9186.65-43.11-77.053.45--0.5903--33.2632.8023.81--6.30--
Medpace Holdings Inc1.89bn282.62m12.43bn5.90k45.5422.1840.216.598.878.8759.2418.221.25--6.84319,634.3018.8013.9444.1623.1827.8128.8415.0015.23--690.220.00--29.1721.7615.2631.1717.99--
Exact Sciences Corp2.50bn-204.15m12.54bn6.50k--3.985,020.645.02-1.14-1.1413.8117.340.39375.3213.82384,579.40-3.22-9.71-3.47-10.6073.8374.10-8.17-28.212.07--0.4311--19.9340.6367.26---3.71--
Incyte Corp3.70bn597.60m12.79bn2.52k21.552.4618.803.462.642.6416.3623.140.58554.435.321,464,203.009.479.0711.6911.0293.7194.9716.1713.683.69--0.00620.008.8714.4575.4240.41-15.06--
Neurocrine Biosciences, Inc.1.89bn249.70m13.72bn1.40k56.726.1050.647.272.432.4318.8422.610.67161.084.781,347,929.008.899.7711.2812.1997.9098.5113.2314.792.40--0.0708--26.7633.1361.6263.902.67--
Charles River Lbrtrs ntrntl Inc4.13bn474.62m13.91bn20.00k29.363.8717.513.379.239.2380.2570.060.52288.195.39206,470.506.086.467.097.6236.8936.9911.6311.581.164.970.42030.003.8612.75-2.3916.6917.86--
Viatris Inc15.43bn54.70m14.18bn38.00k282.070.70055.070.91920.04230.042312.8117.050.31582.495.09405,971.100.1120.08870.13150.106143.6440.290.35460.28911.222.790.4696560.11-5.146.17-97.37-30.53-16.88--
Biomarin Pharmaceutical Inc2.42bn167.65m16.48bn3.40k99.483.3360.586.810.8780.87812.5826.250.36610.51454.42711,327.902.540.77732.930.882578.7276.306.932.241.57--0.180.0015.4210.1618.43---5.74--
Alnylam Pharmaceuticals, Inc.1.83bn-440.24m18.82bn2.10k------10.30-3.59-3.5914.46-1.750.49572.858.43870,615.30-11.94-26.56-15.61-32.7783.0283.66-24.08-94.262.99-2.111.28--76.2389.4561.08---13.29--
Data as of Mar 28 2024. Currency figures normalised to Alnylam Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

57.15%Per cent of shares held by top holders
HolderShares% Held
Capital Research & Management Co. (World Investors)as of 31 Dec 202316.17m12.84%
The Vanguard Group, Inc.as of 31 Dec 202311.65m9.25%
Fidelity Management & Research Co. LLCas of 31 Dec 20239.84m7.81%
Wellington Management Co. LLPas of 31 Dec 20237.21m5.73%
Baillie Gifford & Co.as of 31 Dec 20236.97m5.53%
BlackRock Fund Advisorsas of 31 Dec 20236.05m4.80%
Dodge & Coxas of 31 Dec 20233.67m2.92%
Capital Research & Management Co. (International Investors)as of 31 Dec 20233.59m2.85%
T. Rowe Price Investment Management, Inc.as of 31 Dec 20233.43m2.72%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 20233.39m2.69%
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.